Biomea Fusion (BMEA) Competitors $4.07 -0.16 (-3.78%) (As of 10:40 AM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends BMEA vs. PLRX, ETNB, RLAY, AVXL, IMNM, KURA, KROS, TYRA, ERAS, and CRONShould you be buying Biomea Fusion stock or one of its competitors? The main competitors of Biomea Fusion include Pliant Therapeutics (PLRX), 89bio (ETNB), Relay Therapeutics (RLAY), Anavex Life Sciences (AVXL), Immunome (IMNM), Kura Oncology (KURA), Keros Therapeutics (KROS), Tyra Biosciences (TYRA), Erasca (ERAS), and Cronos Group (CRON). These companies are all part of the "pharmaceutical products" industry. Biomea Fusion vs. Pliant Therapeutics 89bio Relay Therapeutics Anavex Life Sciences Immunome Kura Oncology Keros Therapeutics Tyra Biosciences Erasca Cronos Group Biomea Fusion (NASDAQ:BMEA) and Pliant Therapeutics (NASDAQ:PLRX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, valuation, media sentiment, risk, earnings, analyst recommendations, dividends, community ranking and institutional ownership. Do institutionals & insiders have more ownership in BMEA or PLRX? 96.7% of Biomea Fusion shares are held by institutional investors. Comparatively, 97.3% of Pliant Therapeutics shares are held by institutional investors. 27.6% of Biomea Fusion shares are held by company insiders. Comparatively, 6.4% of Pliant Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Does the media favor BMEA or PLRX? In the previous week, Biomea Fusion had 13 more articles in the media than Pliant Therapeutics. MarketBeat recorded 14 mentions for Biomea Fusion and 1 mentions for Pliant Therapeutics. Biomea Fusion's average media sentiment score of 0.48 beat Pliant Therapeutics' score of 0.00 indicating that Biomea Fusion is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biomea Fusion 3 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Pliant Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more risk & volatility, BMEA or PLRX? Biomea Fusion has a beta of -0.53, meaning that its share price is 153% less volatile than the S&P 500. Comparatively, Pliant Therapeutics has a beta of 1.05, meaning that its share price is 5% more volatile than the S&P 500. Which has preferable earnings & valuation, BMEA or PLRX? Biomea Fusion has higher earnings, but lower revenue than Pliant Therapeutics. Pliant Therapeutics is trading at a lower price-to-earnings ratio than Biomea Fusion, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBiomea FusionN/AN/A-$117.25M-$4.01-1.05Pliant Therapeutics$1.58M508.79-$161.34M-$3.34-3.96 Is BMEA or PLRX more profitable? Pliant Therapeutics' return on equity of -48.91% beat Biomea Fusion's return on equity.Company Net Margins Return on Equity Return on Assets Biomea FusionN/A -118.90% -93.66% Pliant Therapeutics N/A -48.91%-41.09% Do analysts rate BMEA or PLRX? Biomea Fusion currently has a consensus price target of $39.36, indicating a potential upside of 830.58%. Pliant Therapeutics has a consensus price target of $40.50, indicating a potential upside of 206.59%. Given Biomea Fusion's higher possible upside, research analysts clearly believe Biomea Fusion is more favorable than Pliant Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biomea Fusion 0 Sell rating(s) 2 Hold rating(s) 9 Buy rating(s) 2 Strong Buy rating(s) 3.00Pliant Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13 Does the MarketBeat Community prefer BMEA or PLRX? Pliant Therapeutics received 19 more outperform votes than Biomea Fusion when rated by MarketBeat users. Likewise, 74.26% of users gave Pliant Therapeutics an outperform vote while only 68.29% of users gave Biomea Fusion an outperform vote. CompanyUnderperformOutperformBiomea FusionOutperform Votes5668.29% Underperform Votes2631.71% Pliant TherapeuticsOutperform Votes7574.26% Underperform Votes2625.74% SummaryPliant Therapeutics beats Biomea Fusion on 9 of the 17 factors compared between the two stocks. Ad Insiders ExposedNo one’s talking about these Trump tradesAs you likely know, the “Trump bump” launched stocks to record highs after he secured his second reelection bid. Now, Trump and his team are coming to gut government regulation – and it’s going to create some incredible market opportunities. But while the masses chase large-cap tech and so-called AI stocks, a small circle of traders are using a strange but tactical method to find a pool of “hidden Trump trades.”Go here to see how you can start accessing these opportunities today Get Biomea Fusion News Delivered to You Automatically Sign up to receive the latest news and ratings for BMEA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BMEA vs. The Competition Export to ExcelMetricBiomea FusionPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$153.29M$6.57B$5.15B$9.08BDividend YieldN/A2.99%5.12%4.24%P/E Ratio-1.0510.5987.1117.17Price / SalesN/A196.061,116.56117.15Price / CashN/A57.1643.2337.85Price / Book0.895.094.794.78Net Income-$117.25M$151.83M$120.55M$225.60M7 Day Performance-27.69%-1.08%-1.49%-1.36%1 Month Performance-34.32%-4.57%13.65%0.20%1 Year Performance-70.44%8.80%28.61%15.30% Biomea Fusion Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BMEABiomea Fusion3.9182 of 5 stars$4.07-3.8%$39.36+867.2%-70.4%$147.49MN/A-1.0150PLRXPliant Therapeutics3.625 of 5 stars$13.74+3.3%$40.50+194.8%-23.5%$836.08M$1.58M0.0090News CoverageETNB89bio1.7478 of 5 stars$7.85+2.1%$30.33+286.4%-27.2%$833.09MN/A-2.6440RLAYRelay Therapeutics2.273 of 5 stars$4.87+3.4%$20.50+320.9%-63.0%$815.14M$25.55M-1.80304AVXLAnavex Life Sciences3.339 of 5 stars$9.27+9.6%$43.00+363.9%-3.6%$786.10MN/A-18.5440Earnings ReportAnalyst ForecastNews CoverageGap UpIMNMImmunome2.5761 of 5 stars$12.47-0.9%$28.83+131.2%+16.8%$778.34M$10.13M-1.5540Positive NewsKURAKura Oncology4.484 of 5 stars$9.94+3.2%$29.38+195.5%-34.2%$772.93MN/A-4.08142KROSKeros Therapeutics3.3229 of 5 stars$18.80-0.2%$81.33+332.6%-55.4%$761.53M$651,000.00-3.61100Analyst ForecastHigh Trading VolumeTYRATyra Biosciences2.0542 of 5 stars$14.93-0.1%$31.00+107.6%+4.1%$755.46MN/A-9.2820ERASErasca2.0162 of 5 stars$2.60+1.6%$5.90+126.9%+20.4%$735.09MN/A-3.08126CRONCronos Group1.7807 of 5 stars$1.92-0.4%$3.00+56.1%-2.0%$734.86M$87.24M-15.19356News CoverageGap Up Related Companies and Tools Related Companies PLRX Alternatives ETNB Alternatives RLAY Alternatives AVXL Alternatives IMNM Alternatives KURA Alternatives KROS Alternatives TYRA Alternatives ERAS Alternatives CRON Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:BMEA) was last updated on 12/23/2024 by MarketBeat.com Staff From Our PartnersCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredCackling Kamala hates this companyDo you want to see one of the most exciting election trades of all time? A trade that could help America b...DTI | SponsoredWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Behind the Markets | SponsoredMysterious drone activity triggers massive 1,366% surgeIf mysterious drones buzzing over the East Coast weren’t on your radar this year, you’re not alone. But her...Insiders Exposed | SponsoredIf you see ONE chart today… make it this one$1 Trillion… That’s how much Big Tech is set to spend on AI investment in the coming months—according to Go...ProsperityPub | Sponsored70%, 80%, 90% Win Rates? Grab Your Free Cheatsheets Today!Would you like to know the historic win rate of every trade you take before you place it? Well, it’s all po...WealthPress | SponsoredHow Low-Cost Stocks Generate Monthly IncomeAre you ready to transform your investment strategy and generate a steady monthly income? We’re excited to ...Darwin | SponsoredVacuum up cash with these special trades? Have you ever heard about a “volatility vacuum?” Most people haven’t. It all revolves around this formu...Wealthpin Pro | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biomea Fusion, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Biomea Fusion With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
